227 related articles for article (PubMed ID: 21729110)
1. Cancer 'survivor-care': I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment.
Raffa RB
J Clin Pharm Ther; 2011 Aug; 36(4):437-45. PubMed ID: 21729110
[TBL] [Abstract][Full Text] [Related]
2. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
Faghih R; Gfesser GA; Gopalakrishnan M
Recent Pat CNS Drug Discov; 2007 Jun; 2(2):99-106. PubMed ID: 18221220
[TBL] [Abstract][Full Text] [Related]
3. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology.
Thomsen MS; Hansen HH; Timmerman DB; Mikkelsen JD
Curr Pharm Des; 2010 Jan; 16(3):323-43. PubMed ID: 20109142
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
Beinat C; Banister SD; Herrera M; Law V; Kassiou M
CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
[TBL] [Abstract][Full Text] [Related]
5. Activators of α7 nAChR as Potential Therapeutics for Cognitive Impairment.
Wang X; Bell IM; Uslaner JM
Curr Top Behav Neurosci; 2020; 45():209-245. PubMed ID: 32451955
[TBL] [Abstract][Full Text] [Related]
6. Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.
Briggs CA; Grønlien JH; Curzon P; Timmermann DB; Ween H; Thorin-Hagene K; Kerr P; Anderson DJ; Malysz J; Dyhring T; Olsen GM; Peters D; Bunnelle WH; Gopalakrishnan M
Br J Pharmacol; 2009 Nov; 158(6):1486-94. PubMed ID: 19845675
[TBL] [Abstract][Full Text] [Related]
7. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia.
Ishikawa M; Hashimoto K
Curr Pharm Des; 2011; 17(2):121-9. PubMed ID: 21355839
[TBL] [Abstract][Full Text] [Related]
8. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
[TBL] [Abstract][Full Text] [Related]
9. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets?
Thomsen MS; Mikkelsen JD
Curr Drug Targets; 2012 May; 13(5):707-20. PubMed ID: 22300038
[TBL] [Abstract][Full Text] [Related]
10. Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.
Sadigh-Eteghad S; Talebi M; Mahmoudi J; Babri S; Shanehbandi D
Neuroscience; 2015 Jul; 298():81-93. PubMed ID: 25881725
[TBL] [Abstract][Full Text] [Related]
11. Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats.
Thomsen MS; El-Sayed M; Mikkelsen JD
PLoS One; 2011; 6(11):e27014. PubMed ID: 22096516
[TBL] [Abstract][Full Text] [Related]
12. α7-Nicotinic receptors and cognition.
Levin ED
Curr Drug Targets; 2012 May; 13(5):602-6. PubMed ID: 22300026
[TBL] [Abstract][Full Text] [Related]
13. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
[TBL] [Abstract][Full Text] [Related]
14. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
Boess FG; De Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Riedl B; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; Koenig G
J Pharmacol Exp Ther; 2007 May; 321(2):716-25. PubMed ID: 17308038
[TBL] [Abstract][Full Text] [Related]
15. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
Marquis KL; Comery TA; Jow F; Navarra RL; Grauer SM; Pulicicchio C; Kelley C; Brennan JA; Roncarati R; Scali C; Haydar S; Ghiron C; Terstappen GC; Dunlop J
Psychopharmacology (Berl); 2011 Dec; 218(4):635-47. PubMed ID: 21643676
[TBL] [Abstract][Full Text] [Related]
16. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
Martin LF; Freedman R
Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
[TBL] [Abstract][Full Text] [Related]
17. α7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia.
Jones C
J Clin Psychopharmacol; 2018 Jun; 38(3):247-249. PubMed ID: 29505470
[TBL] [Abstract][Full Text] [Related]
18. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia.
Kucinski AJ; Stachowiak MK; Wersinger SR; Lippiello PM; Bencherif M
Curr Pharm Biotechnol; 2011 Mar; 12(3):437-48. PubMed ID: 21133847
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
Potasiewicz A; Nikiforuk A; Hołuj M; Popik P
J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926
[TBL] [Abstract][Full Text] [Related]
20. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
